Aoife Brennan - 10 Nov 2023 Form 4 Insider Report for SYNLOGIC, INC. (SYBX)

Role
President and CEO, Director
Signature
/s/ Aoife Brennan
Issuer symbol
SYBX
Transactions as of
10 Nov 2023
Net transactions value
$0
Form type
4
Filing time
14 Nov 2023, 19:23:02 UTC
Previous filing
09 Jun 2023
Next filing
06 Jun 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYBX Stock Option (right to buy) Disposed to Issuer -5,591 -100% 0 10 Nov 2023 Common Stock 5,591 $202.95 Direct F1, F2
transaction SYBX Stock Option (right to buy) Disposed to Issuer -3,733 -100% 0 10 Nov 2023 Common Stock 3,733 $149.25 Direct F1, F2
transaction SYBX Stock Option (right to buy) Disposed to Issuer -3,600 -100% 0 10 Nov 2023 Common Stock 3,600 $143.25 Direct F1, F2
transaction SYBX Stock Option (right to buy) Disposed to Issuer -9,999 -100% 0 10 Nov 2023 Common Stock 9,999 $118.65 Direct F1, F2
transaction SYBX Stock Option (right to buy) Disposed to Issuer -12,332 -100% 0 10 Nov 2023 Common Stock 12,332 $128.85 Direct F1, F2
transaction SYBX Stock Option (right to buy) Disposed to Issuer -12,352 -100% 0 10 Nov 2023 Common Stock 12,352 $25.50 Direct F1, F3
transaction SYBX Stock Option (right to buy) Disposed to Issuer -18,999 -100% 0 10 Nov 2023 Common Stock 18,999 $52.50 Direct F1, F4
transaction SYBX Stock Option (right to buy) Disposed to Issuer -28,943 -100% 0 10 Nov 2023 Common Stock 28,943 $29.25 Direct F1, F5
transaction SYBX Stock Option (right to buy) Disposed to Issuer -42,999 -100% 0 10 Nov 2023 Common Stock 42,999 $9.30 Direct F1, F6
transaction SYBX Stock Option (right to buy) Disposed to Issuer -8,666 -100% 0 10 Nov 2023 Common Stock 8,666 $9.30 Direct F1, F7
transaction SYBX Stock Option (right to buy) Award +5,591 5,591 10 Nov 2023 Common Stock 5,591 $1.85 Direct F1, F2
transaction SYBX Stock Option (right to buy) Award +3,733 3,733 10 Nov 2023 Common Stock 3,733 $1.85 Direct F1, F2
transaction SYBX Stock Option (right to buy) Award +3,600 3,600 10 Nov 2023 Common Stock 3,600 $1.85 Direct F1, F2
transaction SYBX Stock Option (right to buy) Award +9,999 9,999 10 Nov 2023 Common Stock 9,999 $1.85 Direct F1, F2
transaction SYBX Stock Option (right to buy) Award +12,332 12,332 10 Nov 2023 Common Stock 12,332 $1.85 Direct F1, F2
transaction SYBX Stock Option (right to buy) Award +12,352 12,352 10 Nov 2023 Common Stock 12,352 $1.85 Direct F1, F3
transaction SYBX Stock Option (right to buy) Award +18,999 18,999 10 Nov 2023 Common Stock 18,999 $1.85 Direct F1, F4
transaction SYBX Stock Option (right to buy) Award +28,943 28,943 10 Nov 2023 Common Stock 28,943 $1.85 Direct F1, F5
transaction SYBX Stock Option (right to buy) Award +42,999 42,999 10 Nov 2023 Common Stock 42,999 $1.85 Direct F1, F6
transaction SYBX Stock Option (right to buy) Award +8,666 8,666 10 Nov 2023 Common Stock 8,666 $1.85 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements.
F2 The shares subject to this option are fully vested as of the date hereof.
F3 The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024.
F4 The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025.
F5 The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026.
F6 The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027.
F7 These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met.